Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Iovance Biotherapeutics (IOVA) over the last 8 years, with Q3 2025 value amounting to $466000.0.

  • Iovance Biotherapeutics' Gains from Investment Securities fell 9257.61% to $466000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 3839.2%. This contributed to the annual value of $12.9 million for FY2024, which is 36003.58% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Gains from Investment Securities stood at $466000.0, which was down 9257.61% from $504000.0 recorded in Q2 2025.
  • Iovance Biotherapeutics' Gains from Investment Securities' 5-year high stood at $6.3 million during Q3 2024, with a 5-year trough of $177000.0 in Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Gains from Investment Securities had a median value of $880000.0 in 2024 and averaged $2.0 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Gains from Investment Securities soared by 155620.05% in 2024 and then crashed by 9257.61% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Gains from Investment Securities stood at $186000.0 in 2023, then soared by 373.12% to $880000.0 in 2024, then tumbled by 47.05% to $466000.0 in 2025.
  • Its Gains from Investment Securities was $466000.0 in Q3 2025, compared to $504000.0 in Q2 2025 and $5.6 million in Q1 2025.